$INVA
Innoviva, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023933 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $65.80M $67.26M $107.7M
YoY Change -38.89% -31.27% 18.98%
Cost Of Revenue $10.11M $3.680M
YoY Change
Gross Profit $55.69M $63.58M
YoY Change
Gross Profit Margin 84.63% 94.53%
Selling, General & Admin $17.45M $27.81M $3.113M
YoY Change 460.68% 872.38% -43.4%
% of Gross Profit 31.34% 43.74%
Research & Development $9.985M $11.73M $40.00K
YoY Change 24862.5% 2511.36% -80.0%
% of Gross Profit 17.93% 18.44%
Depreciation & Amortization $7.005M $5.415M $3.456M
YoY Change 102.69% 56.59% 1.65%
% of Gross Profit 12.58% 8.52%
Operating Expenses $31.51M -$219.2M $3.153M
YoY Change 899.33% -6723.36% -44.68%
Operating Profit $24.18M $282.7M
YoY Change 199.03%
Interest Expense -$86.25M $5.096M -$46.45M
YoY Change 85.68% 6.39% -825.75%
% of Operating Profit -356.67% 1.8%
Other Income/Expense, Net -$2.623M $28.00K -$1.590M
YoY Change 64.97% -104.29% 297.5%
Pretax Income -$64.69M $286.4M $56.49M
YoY Change -214.51% 132.53% -37.79%
Income Tax $3.626M $57.10M $10.84M
% Of Pretax Income 19.94% 19.19%
Net Earnings -$68.31M $229.3M $10.35M
YoY Change -760.36% 123.43% -80.81%
Net Earnings / Revenue -103.82% 341.0% 9.61%
Basic Earnings Per Share $3.81
Diluted Earnings Per Share -$0.71 $2.80 $126.7K
COMMON SHARES
Basic Shares Outstanding 69.78M 69.71M 69.49M
Diluted Shares Outstanding 95.83M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.0M $301.1M $201.5M
YoY Change 44.42% 122.83% -18.24%
Cash & Equivalents $291.0M $300.8M $201.5M
Short-Term Investments $282.0K
Other Short-Term Assets $2.933M $2.432M $70.00K
YoY Change 4090.0% 348.71% -95.63%
Inventory $55.90M $70.81M $0.00
Prepaid Expenses
Receivables $64.07M $72.35M $110.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $443.5M $454.6M $313.7M
YoY Change 41.39% 91.87% -8.3%
LONG-TERM ASSETS
Property, Plant & Equipment $170.0K $165.0K $12.00K
YoY Change 1316.67% 1000.0% -57.14%
Goodwill $26.70M $16.00M $0.00
YoY Change
Intangibles $252.9M $258.5M $0.00
YoY Change
Long-Term Investments $403.0M $489.1M $483.8M
YoY Change -16.71% -3.55% 10.39%
Other Assets $4.299M $4.620M $11.00K
YoY Change 38981.82% 3297.06% -94.86%
Total Long-Term Assets $788.0M $873.1M $612.7M
YoY Change 28.6% 34.26% -6.81%
TOTAL ASSETS
Total Short-Term Assets $443.5M $454.6M $313.7M
Total Long-Term Assets $788.0M $873.1M $612.7M
Total Assets $1.231B $1.328B $926.4M
YoY Change 32.93% 49.65% -7.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.939M $3.805M $27.00K
YoY Change 10785.19% 4175.28% -59.09%
Accrued Expenses $33.59M $27.30M $5.780M
YoY Change 481.11% 799.04% -3.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $96.19M $96.13M
YoY Change
Total Short-Term Liabilities $135.0M $163.9M $5.807M
YoY Change 2224.23% 5144.29% -4.96%
LONG-TERM LIABILITIES
Long-Term Debt $444.2M $443.7M $394.7M
YoY Change 12.55% 13.1% 2.37%
Other Long-Term Liabilities $70.92M $78.42M $0.00
YoY Change 560050.0% -100.0%
Total Long-Term Liabilities $515.1M $522.1M $394.7M
YoY Change 30.52% 33.08% 2.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $135.0M $163.9M $5.807M
Total Long-Term Liabilities $515.1M $522.1M $394.7M
Total Liabilities $650.1M $686.0M $400.5M
YoY Change 62.33% 73.48% 2.23%
SHAREHOLDERS EQUITY
Retained Earnings -$204.9M -$136.6M -$456.1M
YoY Change -55.08% -70.72% -36.82%
Common Stock $1.165B $1.172B $1.265B
YoY Change -7.92% -7.23% 0.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $565.8M $641.4M $414.7M
YoY Change
Total Liabilities & Shareholders Equity $1.231B $1.328B $926.4M
YoY Change 32.93% 49.65% -7.32%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$68.31M $229.3M $10.35M
YoY Change -760.36% 123.43% -80.81%
Depreciation, Depletion And Amortization $7.005M $5.415M $3.456M
YoY Change 102.69% 56.59% 1.65%
Cash From Operating Activities $8.899M $15.69M $98.38M
YoY Change -90.95% -83.78% 15.34%
INVESTING ACTIVITIES
Capital Expenditures $34.00K -$11.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$8.644M $97.73M -$19.91M
YoY Change -56.57% -93.69%
Cash From Investing Activities -$8.678M $97.72M -$19.91M
YoY Change -56.4% -93.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00M -96.16M -12.07M
YoY Change -17.11% 1878.26% 382.64%
NET CHANGE
Cash From Operating Activities 8.899M 15.69M 98.38M
Cash From Investing Activities -8.678M 97.72M -19.91M
Cash From Financing Activities -10.00M -96.16M -12.07M
Net Change In Cash -9.780M 17.25M 66.41M
YoY Change -114.73% -81.22% -128.55%
FREE CASH FLOW
Cash From Operating Activities $8.899M $15.69M $98.38M
Capital Expenditures $34.00K -$11.00K $0.00
Free Cash Flow $8.865M $15.70M $98.38M
YoY Change -90.99% -83.77% 15.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-30319
dei Entity Registrant Name
EntityRegistrantName
INNOVIVA, INC.
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001080014
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3265960
dei Entity Address Address Line1
EntityAddressAddressLine1
1350 Old Bayshore Highway Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Burlingame
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94010
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
238-9600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
INVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69783185
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300789000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201525000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
282000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
6743000
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0
CY2022Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
65606000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
110711000
CY2022Q3 us-gaap Inventory Net
InventoryNet
70807000
CY2021Q4 us-gaap Inventory Net
InventoryNet
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7932000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1367000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2432000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
70000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
454591000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
313673000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
489111000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
483845000
CY2022Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
101062000
CY2021Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
111430000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3679000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97000
CY2022Q3 us-gaap Goodwill
Goodwill
15995000
CY2021Q4 us-gaap Goodwill
Goodwill
0
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
258489000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17327000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4620000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11000
CY2022Q3 us-gaap Assets
Assets
1327712000
CY2021Q4 us-gaap Assets
Assets
926395000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3805000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6473000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
619000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5702000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4152000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2849000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
96131000
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
33804000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15120000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1009000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
163884000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5807000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
443679000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
394653000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
78421000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q3 inva Deferred Tax Liability
DeferredTaxLiability
360000
CY2021Q4 inva Deferred Tax Liability
DeferredTaxLiability
0
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69776000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69776000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69566000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69566000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
698000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
696000
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
32005000
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
32005000
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
393829000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
393829000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1171096000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1264024000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136597000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-456148000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
641368000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
414743000
CY2022Q3 us-gaap Minority Interest
MinorityInterest
0
CY2021Q4 us-gaap Minority Interest
MinorityInterest
111192000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641368000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
525935000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1327712000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
926395000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67257000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97862000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
265536000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
284186000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27810000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2860000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46084000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13074000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11725000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
449000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31447000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
536000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1511000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1511000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q3 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
266696000
CY2021Q3 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
266696000
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-20662000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
130000
CY2021Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
33613000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-67881000
us-gaap Gain Loss On Investments
GainLossOnInvestments
133973000
CY2022Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
2135000
CY2021Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
453000
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
3181000
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
503000
CY2022Q3 us-gaap Interest Expense
InterestExpense
5096000
CY2021Q3 us-gaap Interest Expense
InterestExpense
4790000
us-gaap Interest Expense
InterestExpense
11761000
us-gaap Interest Expense
InterestExpense
14229000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-652000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-750000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2036000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
-219167000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
-25315000
us-gaap Operating Expenses
OperatingExpenses
-86101000
us-gaap Operating Expenses
OperatingExpenses
-104601000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
286424000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
123177000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
351637000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
388787000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57077000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20531000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63061000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65600000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
229347000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
102646000
us-gaap Profit Loss
ProfitLoss
288576000
us-gaap Profit Loss
ProfitLoss
323187000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-36176000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
30208000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6341000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
67678000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
265523000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72438000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
282235000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
255509000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.81
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.96
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.63
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69731000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69458000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69640000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86298000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95830000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81699000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95072000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98536000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
229347000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
102646000
us-gaap Profit Loss
ProfitLoss
288576000
us-gaap Profit Loss
ProfitLoss
323187000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
229347000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
102646000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
288576000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
323187000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-36176000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
30208000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
6341000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
67678000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
265523000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
72438000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
282235000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
255509000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
525935000
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
6507000
CY2022Q1 inva Fair Value Of Non Controlling Interest In Subsidiary
FairValueOfNonControllingInterestInSubsidiary
38471000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
214000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
954000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-16585000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
37858000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
552217000
CY2022Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
9545000
CY2022Q2 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
-2000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
68000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1350000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
21371000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
565462000
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
53759000
CY2022Q3 inva Derecognition Of Noncontrolling Interests Upon Sale Of Trc
DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
-61226000
CY2022Q3 inva Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest
DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
-42162000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-11000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3717000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
229347000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
641368000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
607837000
CY2021Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
21285000
CY2021Q1 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
8000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-25000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
451000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
109695000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
696681000
CY2021Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
20161000
CY2021Q2 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
8000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
50000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
110846000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
393745000
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
394149000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
470000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
51000
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
4912000
CY2021Q3 inva Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity
ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
-267000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
542000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
102646000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
491805000
us-gaap Profit Loss
ProfitLoss
288576000
us-gaap Profit Loss
ProfitLoss
323187000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
29258000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
65600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12507000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10376000
inva Amortization Of Inventory Fair Value Adjustments Included In Cost Of Products Sold
AmortizationOfInventoryFairValueAdjustmentsIncludedInCostOfProductsSold
2743000
inva Amortization Of Inventory Fair Value Adjustments Included In Cost Of Products Sold
AmortizationOfInventoryFairValueAdjustmentsIncludedInCostOfProductsSold
0
us-gaap Share Based Compensation
ShareBasedCompensation
6021000
us-gaap Share Based Compensation
ShareBasedCompensation
1463000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1491000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6778000
inva Amortization Of Deferred Royalty Obligation Value Adjustment
AmortizationOfDeferredRoyaltyObligationValueAdjustment
482000
inva Amortization Of Deferred Royalty Obligation Value Adjustment
AmortizationOfDeferredRoyaltyObligationValueAdjustment
0
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-66448000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
132485000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-20662000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
266696000
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-995000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
251000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
867000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-2385000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
7340000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-350000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-277000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-770000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-692000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-328000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3624000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
958000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1709000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-533000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1926000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-2484000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
33804000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
192827000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
265432000
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
58725000
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
46373000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
92951000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
178445000
inva Sale Of Equity Investments Managed By Isp Fund Lp
SaleOfEquityInvestmentsManagedByIspFundLp
24281000
inva Net Proceeds From Sale Of Variable Interest Entity Equity
NetProceedsFromSaleOfVariableInterestEntityEquity
248191000
inva Net Proceeds From Sale Of Variable Interest Entity Equity
NetProceedsFromSaleOfVariableInterestEntityEquity
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
23070000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
inva Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired
CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
150459000
inva Cash Paid For The Acquisition Of La Jolla Pharmaceutical Company Net Of Cash Acquired
CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
0
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95830000
inva Sale Of Equity Investments Managed By Isp Fund Lp
SaleOfEquityInvestmentsManagedByIspFundLp
21426000
inva Purchase And Sale Of Other Investments Managed By Isp Fund Lp
PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
41330000
inva Purchase And Sale Of Other Investments Managed By Isp Fund Lp
PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
-267019000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47956000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63627000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
69811000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
46358000
inva Purchase Of Entasis Noncontrolling Interest
PurchaseOfEntasisNoncontrollingInterest
42395000
inva Purchase Of Entasis Noncontrolling Interest
PurchaseOfEntasisNoncontrollingInterest
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
394149000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
71000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
47000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
342000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
123000
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
165131000
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
0
inva Purchases Of Capped Call Options Associated With Convertible Senior Notes
PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
21037000
inva Purchases Of Capped Call Options Associated With Convertible Senior Notes
PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
252536000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-45567000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-440431000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
99304000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-111372000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201525000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
246487000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300829000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135115000
us-gaap Interest Paid Net
InterestPaidNet
11736000
us-gaap Interest Paid Net
InterestPaidNet
9933000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3859000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300789000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135115000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
40000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
0
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300829000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135115000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Management’s Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partner</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (“API”) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts’ or investors’ expectations, due to a number of important factors.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also started recognizing revenue from product sales as a result of our acquisition of La Jolla. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of our customers each comprise </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of our net product sales and they account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our net product sales from the time of La Jolla</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">’</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s acquisition to September 30, 2022. These same customers account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our receivables from net product sales, which is included in “Accounts receivables, net” in our unaudited consolidated balance sheet as of September 30, 2022.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Item 1A. “Risk Factors” disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 and to the supplemental risk factors detailed in our Form 8-K filed on August 23, 2022 for further detail.</span></p>
inva Number Of Customers
NumberOfCustomers
3
CY2022Q3 inva Decrease To Accumulated Deficit
DecreaseToAccumulatedDeficit
37200000
CY2022Q3 inva Reduction To Additional Paid In Capital
ReductionToAdditionalPaidInCapital
65400000
CY2022Q3 inva Increase In Deferred Tax Assets
IncreaseInDeferredTaxAssets
7400000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
265523000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72438000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
282235000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
255509000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
268698000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
73624000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
291633000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
259062000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69731000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69458000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69640000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86298000
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
128000
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
52000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
94000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
49000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81699000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95072000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98536000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.81
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.96
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.63
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1231000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
891000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
754000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1048000
CY2021Q2 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
20000000.0
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
7700000
CY2022Q3 us-gaap Goodwill
Goodwill
16000000.0
CY2022Q3 inva Intangible Assets Marketed Products Gross
IntangibleAssetsMarketedProductsGross
152500000
CY2022Q3 inva Intangible Assets Marketed Products Accumulated Amortization
IntangibleAssetsMarketedProductsAccumulatedAmortization
-1511000
CY2022Q3 inva Intangible Assets Marketed Products Net
IntangibleAssetsMarketedProductsNet
150989000
CY2022Q3 inva Intangible Assets In Process Research And Development Gross
IntangibleAssetsInProcessResearchAndDevelopmentGross
72100000
CY2022Q3 inva Intangible Assets In Process Research And Development Net
IntangibleAssetsInProcessResearchAndDevelopmentNet
72100000
CY2022Q3 inva Intangible Assets Collaboration Agreement Gross
IntangibleAssetsCollaborationAgreementGross
35400000
CY2022Q3 inva Intangible Assets Collaboration Agreement Net
IntangibleAssetsCollaborationAgreementNet
35400000
CY2022Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
260000000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1511000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
258489000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5757000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
54126000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10924000
CY2022Q3 us-gaap Inventory Net
InventoryNet
70807000
CY2022Q3 inva Accrued Contract Manufacturing Liability
AccruedContractManufacturingLiability
5319000
CY2021Q4 inva Accrued Contract Manufacturing Liability
AccruedContractManufacturingLiability
0
CY2022Q3 inva Accrued Clinical Liability
AccruedClinicalLiability
1062000
CY2021Q4 inva Accrued Clinical Liability
AccruedClinicalLiability
0
CY2022Q3 inva Accrued Research Liability
AccruedResearchLiability
692000
CY2021Q4 inva Accrued Research Liability
AccruedResearchLiability
0
CY2022Q3 inva Accrued Professional Services
AccruedProfessionalServices
3542000
CY2021Q4 inva Accrued Professional Services
AccruedProfessionalServices
894000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1170000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
106000
CY2022Q3 inva Accrued License Fees And Royalties
AccruedLicenseFeesAndRoyalties
1155000
CY2021Q4 inva Accrued License Fees And Royalties
AccruedLicenseFeesAndRoyalties
0
CY2022Q3 us-gaap Other Liabilities
OtherLiabilities
2180000
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
9000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15120000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1009000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2703000
CY2022Q3 inva Deferred Royalty Obligations
DeferredRoyaltyObligations
75424000
CY2022Q3 inva Contingent Value Rights Liability
ContingentValueRightsLiability
294000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
78421000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3717000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
542000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6021000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1463000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
549704000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
433484000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
9894000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
38831000
CY2022Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
539810000
CY2021Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
394653000
CY2022Q3 us-gaap Debt Current
DebtCurrent
96131000
CY2021Q4 us-gaap Debt Current
DebtCurrent
0
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
443679000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
394653000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
96204000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
192500000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0
CY2022Q3 inva Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
261000000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
549704000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
640000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1101000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
35000
us-gaap Variable Lease Cost
VariableLeaseCost
110000
CY2022Q3 us-gaap Lease Cost
LeaseCost
675000
us-gaap Lease Cost
LeaseCost
1211000
us-gaap Operating Lease Payments
OperatingLeasePayments
540000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3323000
inva Right Of Use Assets Obtained Through Acquistions
RightOfUseAssetsObtainedThroughAcquistions
1185000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3679000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1170000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
106000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2703000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3873000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
106000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
250000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1542000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1269000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1289000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4350000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
477000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3873000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63100000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65600000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.183
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.169

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-023933-index-headers.html Edgar Link pending
0000950170-22-023933-index.html Edgar Link pending
0000950170-22-023933.txt Edgar Link pending
0000950170-22-023933-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inva-20220930.htm Edgar Link pending
inva-20220930.xsd Edgar Link pending
inva-ex31_1.htm Edgar Link pending
inva-ex31_2.htm Edgar Link pending
inva-ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
inva-20220930_lab.xml Edgar Link unprocessable
inva-20220930_pre.xml Edgar Link unprocessable
inva-20220930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
inva-20220930_cal.xml Edgar Link unprocessable
inva-20220930_def.xml Edgar Link unprocessable